Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A vaccination strategy for the prevention of hepatitis C virus (HCV) remains an important goal for the global elimination of HCV. An HCV vaccine would have major benefits for people at risk of HCV infection and would be a major contributor, possibly essential for population strategies that aim to eliminate infection. Current vaccine efforts primarily utilize either the antibody response to structural HCV proteins or a T-cell response targeting the HCV genome more widely. T-cell vaccines aim to abort acute infection and prevent the development of chronic disease. While the exact immune correlates of protection against HCV are not fully understood, both B-cell and T-cell immunity are associated with spontaneous resolution of HCV infection. Therefore, a combination of approaches in an HCV vaccine strategy to harness T-cell and B-cell responses may provide the best chance of successfully clearing an acute HCV infection.

Original publication





Book title

Clinical Dilemmas in Viral Liver Disease, Second Edition

Publication Date



208 - 215